Evidence map›Paper›PMID 29062551›Full record

ArticleSultan Qaboos University medical journal2017

Hamidreza Mohammadi, Jafar Jalilian, Mohammad Y Karimi, Seyed V Shetab-Boushehri

Erratum issuedOpen access · diamondAbstract read
In one paragraph

Article in Sultan Qaboos University medical journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.0field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Erratum Notice of Formatting Correction:Sultan Qaboos University medical journal · 2017
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Hamidreza MohammadiPharmaceutical Sciences Research Center, Hemoglobinopathy Institute, Mazandaran University of Medical Sciences, Sari, Iran.
Jafar JalilianDepartment of Toxicology & Pharmacology, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran.
Mohammad Y KarimiRazi Drug Research Center, School of Pharmacy, International Campus, Iran University of Medical Sciences, Tehran, Iran.
Seyed V Shetab-BoushehriRazi Drug Research Center, School of Pharmacy, International Campus, Iran University of Medical Sciences, Tehran, Iran.
Mazandaran University of Medical Sciences · IRIran University of Medical Sciences · IRRazi Hospital · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesOrganophosphate (OP) pesticides inhibit both red blood cell (RBC) and plasma cholinesterases (ChEs). Oximes, especially pralidoxime (2-PAM), are widely used as antidotes to treat OP poisoning. In addition, N-acetylcysteine (NAC) is sometimes used as an adjuvant antidote. The current study aimed to assess the feasibility of using NAC as a single therapeutic agent for OP poisoning in comparison to

methodsThis study was carried out at the Razi Drug Research Center of Iran University of Medical Sciences, Tehran, Iran, between April and September 2014. A total of 22 healthy human subjects were recruited and 8 mL citrated blood samples were drawn from each subject. Dichlorvos-inhibited blood samples were separately exposed to low and high doses (final concentrations of 300 and 600 μmol.L

resultsAlthough cysteine-and not NAC-increased the ChE activity of both plasma and RBCs over those of dichlorvos, it did not increase them over those of a high dose of 2-PAM.

conclusionThese results suggest that the direct reactions of 2-PAM and cysteine with dichlorvos and the reactivation of phosphorylated ChEs occurr via an associative stepwise addition-elimination process. High therapeutic blood concentrations of cysteine are needed for the elevation of ChE activity in plasma and RBCs; however, both this agent and NAC may still be effective in the reactivation of plasma and RBC ChEs.

Indexed as

Cholinesterase InhibitorsEnzyme ActivationAcetylcysteineAntidotesCholinesterase ReactivatorsCholinesterasesCysteineDichlorvosErythrocytesFeasibility StudiesHumansInsecticidesIn Vitro TechniquesIranOrganophosphate PoisoningPralidoxime CompoundsAcetylcysteineAntidotesCholinesterase InhibitorsCholinesterase ReactivatorsCholinesterasesCysteineDichlorvosInsecticidesPralidoxime CompoundsAntidotesCholinesterasesCysteineN-AcetylcysteineOrganophosphate PoisoningPralidoxime Compounds

Identifiers

PMID29062551
PMCPMC5642358
OpenAlexW2761628774

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.